Unproven stem cell treatments: Is the US Supreme Court sending a message?
By Patrick Foong,
BioNews
| 11. 03. 2025
A Supreme Court decision affirms the FDA's regulatory oversight of stem-cell-based treatments. Dr Patrick Foong explains the implications for stem cell clinics and their patients...
Recently, the US Supreme Court declined to hear an appeal from stem cell clinics, which challenged the Food and Drug Administration (FDA)'s authority to regulate unproven stem cell treatments.
In California Stem Cell Treatment v United States, the Supreme Court refused to review the decision of the Court of Appeals for the Ninth Circuit, and denied the Goldwater Institute's motion to file a related brief for consideration. This decision means that the previous ruling will stand, affirming the FDA's regulatory oversight of stem-cell-based treatments (see BioNews 1260). This has important implications for stem cell clinics and their patients.
The FDA has become concerned about for-profit entities that advertise stem cell therapies as treatments for various diseases and medical conditions, without robust scientific evidence supporting the safety and efficacy of these medical procedures. In 2017, the agency developed governance for regulating regenerative medicine products and cellular therapies. Moreover, it expressed the intention to expand enforcement of rules relating to cellular therapies. The FDA has brought lawsuits to prevent unscrupulous stem cell businesses from administering stem cell products derived...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
